EPS of $-0.40 increased by 75.9% from previous year
Net income of -2.68M
"N/A" - N/A
MEI Pharma Inc (MEIP) QQ2 2025 Results – Cash Position Strengthened Amid Ongoing Net Loss with Pipeline Catalysts in Oncology
Executive Summary
MEI Pharma reported a Q2 2025 period with no reported revenue and a net loss of $2.68 million, driven primarily by ongoing R&D and G&A expenses. R&D expense of $0.308 million combined with G&A of $3.143 million yielded an operating loss of $3.451 million and an EBITDA of negative $3.451 million. A non-operating gain of $0.774 million partially offset operating losses, resulting in a pre-tax loss of $2.678 million and a net loss of $2.678 million, or −$0.40 per share, on 6.663 million weighted-average shares. In cash flow terms, operating cash flow was negative at −$3.666 million, while MEI benefited from maturities of investments totaling approximately $19.953 million, producing a net increase in cash of roughly $16.787 million for the period. Ending cash stood at $23.739 million against total current assets of $24.385 million and total liabilities of $2.287 million, yielding a robust liquidity position (current ratio ~10.66x). The company’s balance sheet reflects a substantial retained earnings deficit (−$398.903 million) but a stockholders’ equity position of $22.098 million, aided by sizable accumulated other comprehensive income/stockholders’ equity components. Importantly, MEI does not generate revenue in the near term and remains dependent on its pipeline and partnering activities for value realization.
Key Performance Indicators
Operating Income
-3.45M
QoQ: 58.68% | YoY:71.07%
Net Income
-2.68M
QoQ: 66.57% | YoY:75.80%
EPS
-0.40
QoQ: 66.67% | YoY:75.90%
Revenue Trend
Margin Analysis
Key Insights
Revenue: $0 (no reported revenue for Q2 2025); YoY/QoQ revenue data not applicable due to non-revenue quarter.
Operating income: −$3.451 million, vs. prior periods showing larger losses; YoY change reported as +71.07% (improvement in year-over-year comparison) and QoQ change of +58.68% (sequential improvement in operating loss).
Net income: −$2.678 million; YoY change +75.80% and QoQ change +66.57%, reflecting a reduced net loss relative to the prior-year and prior-quarter periods.
Earnings per share (diluted): −$0.40; YoY +75.90% and QoQ +66.67% (driven by lower net loss and share count stability).
EBITDA: −$3.451 million (aligned with operating loss given the absence of depreciation/amortization data in the period).
Financial Highlights
Key quarterly metrics and trend observations:
- Revenue: $0 (no reported revenue for Q2 2025); YoY/QoQ revenue data not applicable due to non-revenue quarter.
- Operating income: −$3.451 million, vs. prior periods showing larger losses; YoY change reported as +71.07% (improvement in year-over-year comparison) and QoQ change of +58.68% (sequential improvement in operating loss).
- Net income: −$2.678 million; YoY change +75.80% and QoQ change +66.57%, reflecting a reduced net loss relative to the prior-year and prior-quarter periods.
- Earnings per share (diluted): −$0.40; YoY +75.90% and QoQ +66.67% (driven by lower net loss and share count stability).
- EBITDA: −$3.451 million (aligned with operating loss given the absence of depreciation/amortization data in the period).
- Cash flow: Operating cash flow −$3.666 million; Free cash flow −$3.666 million; Net change in cash +$16.787 million aided by maturities of investments totaling $19.953 million.
- Balance sheet highlights: Cash and cash equivalents $23.739 million; Total assets $24.385 million; Total current liabilities $2.287 million; Total stockholders’ equity $22.098 million; Retained earnings deficit $(398.903) million; Net debt to cash is negative (net cash position) at −$23.739 million.
- Liquidity ratios: Current ratio 10.66, Cash ratio 10.38, indicating ample liquidity relative to near-term obligations.
- Valuation context: Price/earnings negative due to losses; Enterprise value multiple 2.13x; Price-to-book ratio 0.742x; Cash per share $3.56. These metrics reflect a biotech pre-revenue profile with a pipeline-centric value proposition.
Income Statement
Metric
Value
YoY Change
QoQ Change
Operating Income
-3.45M
71.07%
58.68%
Net Income
-2.68M
75.80%
66.57%
EPS
-0.40
75.90%
66.67%
Key Financial Ratios
currentRatio
10.66
returnOnAssets
-11%
returnOnEquity
-12.1%
operatingCashFlowPerShare
$-0.55
freeCashFlowPerShare
$-0.55
priceToBookRatio
0.74
priceEarningsRatio
-1.53
Net Income vs. Revenue
Expense Breakdown
Management Commentary
Transcript insights unavailable: No earnings call transcript data were provided for QQ2 2025 in the supplied material. Consequently, management-specific takeaways, strategic tone, and concrete quotes could not be extracted from an earnings call. Investors should monitor forthcoming quarterly calls for commentary on pipeline milestones, potential licensing deals, and updated guidance.
N/A
— N/A
N/A
— N/A
Forward Guidance
Forward-looking assessment rests on MEI’s clinical pipeline and potential partnership/licensing catalysts rather than current revenue generation:
- Pipeline catalysts to watch include Zandelisib in Phase III for relapsed/refractory follicular lymphoma and Vorucilib/ME344/Pracinostat programs across hematologic and solid tumor contexts. Positive Phase III data or meaningful trial readouts could unlock milestone payments or licensing discussions with strategic partners, potentially improving balance sheet flexibility.
- Management commentary on timelines, enrollment progress, and any potential strategic collaborations would be a key driver of share price sensitivity. Given the current non-revenue status, outcomes hinge on clinical success and partner economics rather than near-term product revenue.
- Industry dynamics in oncology (immuno-oncology and targeted therapies) provide a favorable backdrop for a pipeline-focused biotech, but the path to revenue remains extended and contingent on successful trials and regulatory approvals. Monitor for any capital market activities to bolster runway if trial timelines extend beyond a 12–24 month horizon.
Competitive Position
Company
Gross Margin
Operating Margin
Return on Equity
P/E Ratio
MEIP Focus
0.00%
0.00%
-12.10%
-1.53%
ELDN
0.00%
0.00%
5.28%
-59.10%
KZR
0.00%
0.00%
-14.30%
-49.38%
NXTC
0.00%
0.00%
-18.00%
-68.10%
VSTM
99.90%
-1.83%
-20.60%
-2.64%
Gross Profit Margin
Operating Profit Margin
Return on Equity
P/E Ratio Comparison
Investment Outlook
MEI Pharma remains a pipeline-centric biotechnology stock characterized by a meaningful cash runway but no current revenue. The near-term investment thesis hinges on upcoming clinical milestones and potential partner-driven milestones or licensing deals. The company’s liquidity cushion reduces near-term default risk, yet substantial execution risk persists given the absence of revenue and reliance on successful trial outcomes. If pivotal data from Zandelisib or other programs signals meaningful efficacy, MEIP could realize upside through partnerships or potential commercialization. Conversely, any adverse trial data or delays could compress the valuation multiple and necessitate additional fundraising, with the risk of equity dilution.
Recommendation: Maintain a high-risk, high-reward stance. Track quarterly updates for clinical readouts, partnerships, and any updated guidance on runway; sensitivity to pipeline milestones is high for MEI’s equity trajectory.
Key Investment Factors
Growth Potential
High-potential if pivotal trial data for Zandelisib (Phase III in RRFL) and other programs yield positive efficacy signals; potential milestone payments or licensing agreements could unlock near-term value realization. A successful collaboration with major pharma partners (e.g., Kyowa Kirin, Beigene, Helsinn) can de-risk development and accelerate commercialization upside.
Profitability Risk
Clinical development risk is high given the lack of revenue and continued losses. Regulatory delays, negative trial results, or unfavorable trial designs could significantly impact the value trajectory. Financing risk exists given the burn profile; although MEI currently exhibits strong liquidity, future equity raises or debt financings could dilute existing shareholders. Competitive landscape in oncology and specialty hematology poses ongoing threats.
Financial Position
Solid liquidity buffer with $23.739M cash and equivalents and minimal short-term liabilities. The cash runway is supported by maturities of investments (approx. $19.953M) that boosted cash at period end. However, sustained operating losses and cash burn require either pipeline-driven milestones or additional financing to sustain long-term development.
SWOT Analysis
Strengths
Healthy liquidity position with cash and equivalents of $23.739M and current ratio of 10.66x.
Robust pipeline with multiple oncology programs (Zandelisib, Vorucilib, ME344, Pracinostat) across Phases I-III, supported by collaborations with Kyowa Kirin, BeiGene, Helsinn, and Presage.
Potential for milestone payments or licensing deals from strategic partners to fund development milestones.
Weaknesses
No revenue generation in QQ2 2025; ongoing net losses for MEI, reflecting early-stage biotech risk.
Dependence on successful clinical outcomes and partner deals for value realization; pipeline risk remains high.
Significant retained earnings deficit on the balance sheet, signaling long-term cumulative losses.
Opportunities
Catalysts from pivotal trial results (Zandelisib in RRFL) and potential expansion into additional B-cell malignancies.
Strategic partnerships and licensing opportunities in a favorable oncology market could unlock upfronts and milestones.
Potential expansion of ME344/Pracinostat programs into additional indications or combination strategies.
Threats
Clinical trial failures or delays could severely impact valuation and funding needs.
Intense competition in lymphoma and hematologic malignancies from larger pharma players and other biotech entrants.
Macro financing conditions and dilution risk if external funding is required to sustain operations.